Products for Research Use Only

Deferasirox-d4

CAT: 0804-HY-17359S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17359S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Deferasirox-d4 is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload[1][2][3].
CAS Number
1133425-75-8
UNSPSC
12352005
Hazard Statement
H315-H319-H335
Target
Bacterial; Ferroptosis; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Apoptosis; Others
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
OC1=C(C=CC=C1)C2=NC(C3=C(C=CC=C3)O)=NN2C4=C([2H])C([2H])=C(C([2H])=C4[2H])C(O)=O
Molecular Formula
C21H11D4N3O4
Molecular Weight
377.39
Precautions
P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Sobbe A, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30 (3) :638-45.|[3]Kim JL, et al. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targetingcaspase. Acta Haematol. 2011;126 (4) :241-5.|[4]Lee DH, et al. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status. Exp Hematol. 2013 Jun;41 (6) :539-46.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported